CDC vaccine recommendations stall as federal policy overhaul faces legal challenges.

The FDA has approved mFlusiva, an mRNA flu vaccine that tested well in older adults, but the CDC has not issued guidance on its use, illustrating a broader breakdown in federal vaccine recommendations. Health Secretary Robert F. Kennedy Jr.’s overhaul of the Advisory Committee on Immunization Practices, which had guided CDC policy for decades, was challenged in court; a judge halted the replacement panel and suspended efforts to reduce recommended childhood vaccines, but the ruling did not restore the previous process. As a result, guidance on new vaccines has stalled and public forums for weighing vaccine policy questions have diminished. Medical groups welcomed the court ruling, while experts warned that the disruption and weakened trust in the administration’s vaccine recommendations could leave doctors and the public without a clear, evidence-based path for decisions.
ACIP had previously recommended giving an RSV vaccine to pregnant women between September and January in most of the United States, aligning vaccination with the season when RSV infections are most common and helping protect newborns.
mFlusiva is the first flu vaccine made using mRNA technology, and the FDA granted it full approval for people ages 50 to 64. Article 2 also reports that Kennedy had criticized mRNA vaccines and canceled contracts for developing new ones.
American College of Physicians president Dr. Jason Goldman said he hoped the court ruling would lead to “a return to a transparent and evidence-driven process” that protects communities and serves patients.
A public-health researcher cited in Article 2 warned that distrust in the Trump administration’s vaccine recommendations could extend even to recommendations that align with the views of mainstream medical and public-health communities.
Publishers
8
Articles
164
Reach
172